Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and
metastasis through various mechanisms and is now recognized as a hallmark of cancer and …

The interaction of the host immune system with tumor cells in the tissue microenvironment is
essential in understanding tumor immunity and development of successful cancer …

PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic
microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is …

Background We assessed the safety, efficacy, and pharmacokinetics of the transforming
growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti …

Complex rearrangement patterns and mitotic errors are hallmarks of most pancreatic ductal
adenocarcinomas (PDAC), a disease with dismal prognosis despite some therapeutic …

The advent of immunotherapy and targeted therapies has dramatically changed the
outcomes of patients affected by many malignancies. Pancreatic cancer (PC) remains one …

Intratumoral cytotoxic CD8+ T cells (CTL) enter a dysfunctional state characterized by
expression of coinhibitory receptors, loss of effector function, and changes in the …

PURPOSE Pancreatic cancer (PC) carries a poor prognosis with high rates of unresectable/
metastatic disease at diagnosis, recurrence after resection, and few systemic therapy …

Cancer immunotherapy targeting immune checkpoints has exhibited promising clinical
outcomes in many cancers, but it offers only limited benefits for pancreatic cancer (PC) …

Pancreatic ductal adenocarcinoma (PDAC) is associated with poor survival. Of all newly
diagnosed patients, only about 20% can benefit from a potentially curative surgical …